Ethical challenges in preclinical alzheimer's ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Ethical challenges in preclinical alzheimer's disease observational studies and trials: results of the barcelona summit
Auteur(s) :
Molinuevo, Jose Luis [Auteur]
Cami, Jordi [Auteur]
Carne, Xavier [Auteur]
Carrillo, Maria C. [Auteur]
Georges, Jean [Auteur]
Isaac, Maria B. [Auteur]
Khachaturian, Zaven [Auteur]
Kim, Scott Y H. [Auteur]
Morris, John C. [Auteur]
Pasquier, Florence [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U1171
Ritchie, Craig [Auteur]
Sperling, Reisa [Auteur]
Karlawish, Jason [Auteur]
Cami, Jordi [Auteur]
Carne, Xavier [Auteur]
Carrillo, Maria C. [Auteur]
Georges, Jean [Auteur]
Isaac, Maria B. [Auteur]
Khachaturian, Zaven [Auteur]
Kim, Scott Y H. [Auteur]
Morris, John C. [Auteur]
Pasquier, Florence [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U1171
Ritchie, Craig [Auteur]
Sperling, Reisa [Auteur]
Karlawish, Jason [Auteur]
Titre de la revue :
Alzheimer's & dementia . the journal of the Alzheimer's Association
Nom court de la revue :
Alzheimers. Dement.
Numéro :
12
Pagination :
614-622
Date de publication :
2016-05-01
ISSN :
1552-5260
Mot(s)-clé(s) en anglais :
Alzheimer''s disease
Asymptomatic
Ethics
Preclinical AD
Asymptomatic
Ethics
Preclinical AD
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Alzheimer's disease (AD) is among the most significant health care burdens. Disappointing results from clinical trials in late-stage AD persons combined with hopeful results from trials in persons with early-stage suggest ...
Lire la suite >Alzheimer's disease (AD) is among the most significant health care burdens. Disappointing results from clinical trials in late-stage AD persons combined with hopeful results from trials in persons with early-stage suggest that research in the preclinical stage of AD is necessary to define an optimal therapeutic success window. We review the justification for conducting trials in the preclinical stage and highlight novel ethical challenges that arise and are related to determining appropriate risk-benefit ratios and disclosing individuals' biomarker status. We propose that to conduct clinical trials with these participants, we need to improve public understanding of AD using unified vocabulary, resolve the acceptable risk-benefit ratio in asymptomatic participants, and disclose or not biomarker status with attention to study type (observational studies vs clinical trials). Overcoming these challenges will justify clinical trials in preclinical AD at the societal level and aid to the development of societal and legal support for trial participants.Lire moins >
Lire la suite >Alzheimer's disease (AD) is among the most significant health care burdens. Disappointing results from clinical trials in late-stage AD persons combined with hopeful results from trials in persons with early-stage suggest that research in the preclinical stage of AD is necessary to define an optimal therapeutic success window. We review the justification for conducting trials in the preclinical stage and highlight novel ethical challenges that arise and are related to determining appropriate risk-benefit ratios and disclosing individuals' biomarker status. We propose that to conduct clinical trials with these participants, we need to improve public understanding of AD using unified vocabulary, resolve the acceptable risk-benefit ratio in asymptomatic participants, and disclose or not biomarker status with attention to study type (observational studies vs clinical trials). Overcoming these challenges will justify clinical trials in preclinical AD at the societal level and aid to the development of societal and legal support for trial participants.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
CHU Lille
CNRS
Inserm
Université de Lille
CNRS
Inserm
Université de Lille
Collections :
Équipe(s) de recherche :
Troubles cognitifs dégénératifs et vasculaires
Date de dépôt :
2019-11-27T13:38:07Z